In this issue of Structure, Mabanglo et al. characterize five ClpP agonists termed TRs. The co-crystal structures reveal more robust shape and charge complementarities than the anti-cancer agent ONC201. These novel compounds are of potential therapeutic interest because they enhance ClpP proteolytic activity and have an inhibitory effect on tumor cell growth.

中文翻译：

---

对人类 ClpP 激活剂进化简化的结构洞察

在本期结构中，Mabanglo 等人。表征称为 TRs 的五种 ClpP 激动剂。与抗癌剂 ONC201 相比，共晶结构显示出更稳健的形状和电荷互补性。这些新型化合物具有潜在的治疗意义，因为它们增强了 ClpP 蛋白水解活性并对肿瘤细胞生长具有抑制作用。